Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria
International Archives of Allergy and Immunology · 2024
DOI: 10.1159/000538291 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Zeynep Keskinkaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Immunoglobulin E. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Two distinct chronic spontaneous urticaria (CSU) endotypes, IgE-mediated autoallergic and IgG-mediated autoimmune, were defined based on the response patterns to omalizumab. However, the coexistence of IgE and IgG autoantibodies in a subset of patients might complicate the prediction of the treatment outcomes. This study aimed to evaluate the effectiveness and safety of omalizumab in CSU patients, focusing on the factors predicting the response patterns.
Methods
This was a retrospective cross-sectional single-center study investigating CSU patients treated with omalizumab for at least 6 months between September 2015 and February 2023. Patients were evaluated regarding demographics, clinical findings, baseline laboratory parameters, treatment outcomes, and side effects. Early and late responders were defined depending on the time for response, within or after 3 months, respectively.
Results
Among 82 patients, 75 (91.5%) responded to omalizumab during the first 6 months, classified as early (n = 51) and late responders (n = 24). The IgG anti-thyroid peroxidase (anti-TPO)/total IgE ratio was an independent predictor for determining the speed of response (p < 0.05). Of 29 patients who discontinued omalizumab, 19 (65.5%) experienced relapse with a good response to retreatment (n = 18/19, 94.7%). Early responders relapsed more frequently than late responders (77.3% vs. 28.6%) (p < 0.05). Only mild side effects were observed in a minority of patients (n = 8/82, 9.8%).
Conclusion
Omalizumab is an effective and safe treatment in CSU. The IgG anti-TPO/total IgE ratio seems a valuable tool to predict the early and late responders, the former having a higher possibility of relapse upon drug withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey.
Zitieren
APA
Keskinkaya, Z., Kaya, Ö., Işık Mermutlu, S., & Öğretmen, Z. (2024). Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology. https://doi.org/10.1159/000538291
Vancouver
Keskinkaya Z, Kaya Ö, Işık Mermutlu S, Öğretmen Z. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology. 2024. doi:10.1159/000538291
BibTeX
@article{Keskinkaya2024,
author = {Keskinkaya, Zeynep and Kaya, Özge and Işık Mermutlu, Selda and Öğretmen, Zerrin},
title = {Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria},
journal = {International Archives of Allergy and Immunology},
year = {2024},
doi = {10.1159/000538291}
}
EUVIMED